These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2800822)

  • 1. [Effect of Essentiale on the blood lipid indicators in progressive Duchenne muscular dystrophy].
    Islamova IB; Grinio LP
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(7):83-5. PubMed ID: 2800822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dynamics of blood lipids and indicators of lipid peroxidation and energy metabolism after administration of Essentiale to patients with ischemic heart disease].
    Serkova VK
    Klin Med (Mosk); 1986 Jul; 64(7):91-5. PubMed ID: 3762044
    [No Abstract]   [Full Text] [Related]  

  • 3. [Blood lipid disorders in Becker-Kiner progressive muscular dystrophy].
    Islamova IB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):346-8. PubMed ID: 3993293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypolipidemic action of phospholipid compounds in experimental animals].
    Okunevich IV; Ryzhenkov VE; Ulesov AV; Makarevich IF; Mokrouz MV; Davigora IV
    Vopr Pitan; 1994; (3):19-21. PubMed ID: 7975417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lipoid changes in progressive muscular dystrophy].
    Schellnack K
    Beitr Orthop Traumatol; 1970 Jan; 17(1):91-5. PubMed ID: 5511214
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of a phospholipid preparation on blood lipids].
    Ciammaichella A
    Minerva Med; 1971 Nov; 62(84):4138-41. PubMed ID: 5136616
    [No Abstract]   [Full Text] [Related]  

  • 7. Biophysical studies of erythrocyte membranes from patients with duchenne muscular dystrophy.
    Dellantonio R; Angeleri F; Capriotti M; Lenaz G; Curatola G; Mazzanti L; Bertoli E
    Ital J Biochem; 1980; 29(2):121-8. PubMed ID: 6250994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasma lipids of patients with Duchenne's muscular dystrophy at different stages of the disease].
    Temin PA; Islamova IB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(11):1632-6. PubMed ID: 6675360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical role of lipid metabolism indices in the plasma and erythrocytes in progressive muscular dystrophies].
    Badalian LO; Islamova IB; Grinio LP; Temin PA; Tananova GV
    Vopr Med Khim; 1985; 31(3):81-5. PubMed ID: 4024535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular organization of erythrocyte membranes in Duchenne muscular dystrophy].
    Falcioni AM; Ferretti G; Mazzanti L; Curatola G
    Boll Soc Ital Biol Sper; 1981 Dec; 57(23):2307-12. PubMed ID: 6279127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intellectual function in Duchenne muscular dystrophy: the influence of penicillamine.
    Buchanan DC; Roelofs RI; White DK; Saavedra de Arango G
    Arch Phys Med Rehabil; 1981 Dec; 62(12):623-5. PubMed ID: 7032457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Erythrocyte membrane in Duchenne muscular dystrophy. II. Fluidity of lipids in dystrophic patients and their families].
    Zolese G; Campagnoli P; Colombi A; Mazzanti L
    Boll Soc Ital Biol Sper; 1980 Dec; 56(23):2403-7. PubMed ID: 6258613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
    Kałka D; Sobieszczańska M; Kopka L; Marciniak W; Zawadzka-Bartczak E; Bak A; Popielewicz-Kautz A; Korzeniowska J; Janczak J; Adamus J
    Pol Merkur Lekarski; 2007 Feb; 22(128):101-6. PubMed ID: 17598652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suggestion for a possible mitigating treatment of Duchenne muscular dystrophy.
    Zatz M; Frota-Pessoa O
    Am J Med Genet; 1981; 10(3):305-7. PubMed ID: 7304675
    [No Abstract]   [Full Text] [Related]  

  • 15. Antilipaemic drugs and nephrotic hyperlipidaemia.
    Edwards KD
    Prog Biochem Pharmacol; 1972; 7():370-426. PubMed ID: 4567423
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy.
    Zatz M; Rapaport D; Vainzof M; Pavanello Rde C; Rocha JM; Betti RT; Otto PA
    Am J Med Genet; 1988 Dec; 31(4):821-33. PubMed ID: 3239574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cardiac problems in patients with progressive muscular dystrophy].
    Danzig V; Fiksa J; Hani AB; Havlová M; Sonka K
    Sb Lek; 2003; 104(3):273-8. PubMed ID: 15224533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic trial of isaxonine in Duchenne muscular dystrophy.
    Heckmatt JZ; Hyde SA; Gabain A; Dubowitz V
    Muscle Nerve; 1988 Aug; 11(8):836-47. PubMed ID: 3050510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic trial with allopurinol in progressive muscular dystrophy (author's transl)].
    Pineda M; Fábregues I; Campistol J; Fernández Alvarez E; Alvarez M
    An Esp Pediatr; 1982 Jan; 16(1):42-6. PubMed ID: 7044206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-benefit analysis of the therapy of lipid metabolism disorders].
    Karádi I
    Orv Hetil; 1996 May; 137(21):1164. PubMed ID: 8757110
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.